DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Monday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of DBV Technologies in a research note on Wednesday, February 21st.

DBV Technologies Stock Performance

NASDAQ:DBVT opened at $0.67 on Monday. The stock’s fifty day moving average price is $0.75 and its two-hundred day moving average price is $0.84. DBV Technologies has a 52-week low of $0.65 and a 52-week high of $2.37. The company has a market cap of $129.22 million, a price-to-earnings ratio of -1.72 and a beta of 0.73.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.10. DBV Technologies had a negative return on equity of 46.33% and a negative net margin of 461.32%. The firm had revenue of $8.88 million for the quarter, compared to the consensus estimate of $1.10 million. During the same quarter in the prior year, the business earned ($0.23) EPS. On average, equities analysts predict that DBV Technologies will post -0.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DBVT. Cowen AND Company LLC acquired a new stake in DBV Technologies during the 4th quarter worth $49,000. Optiver Holding B.V. raised its stake in DBV Technologies by 595.2% during the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after buying an additional 235,337 shares during the period. Finally, Landscape Capital Management L.L.C. acquired a new stake in DBV Technologies during the 3rd quarter worth $94,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.